Pharma & Biotech Most Active Sector in UK M&As
The pharma, medical and biotech (PMB) sector, driven by the Novartis’s £8.6bn acquisition of GlaxoSmithKline’s oncology division, was the most active industry in UK M&A in H1 2014, with a 26.9% market share (£10.1bn), according to Mergermarket’s latest deal round-up.
The pharma, medical and biotech (PMB) sector, driven by the Novartis’s £8.6bn acquisition of GlaxoSmithKline’s oncology division, was the most active industry in UK M&A in H1 2014, with a 26.9% market share (£10.1bn), according to Mergermarket’s latest deal round-up.
However M&A activity targeting the United Kingdom - standing at £37.5bn in H1 2014 - represented the lowest half-year value since H1 2010 (£37 bn) and a 12.5% drop from H1 2013 (£42.9bn).
The Novartis acquisition was the only mega-deal in the region so far, and the lack of large transactions pulled the UK M&A value down in Q1. However, the second quarter witnessed a stark improvement (up 156.5% from Q1, from £10.5bn to £27bn) and represented the highest quarterly value in the country since Q2 2012. Needless to say, the proportion of PMB M&A in the UK and globally would have been considerably larger if the £69bn proposed acquisition of AstraZeneca by Pfizer had gone through.
http://www.mergermarket.com/pdf/MergermarketTrendReport.H12014.UK.pdf
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.
